JPH0510952A - Preparation of carrier containing immobilized substance - Google Patents
Preparation of carrier containing immobilized substanceInfo
- Publication number
- JPH0510952A JPH0510952A JP16588491A JP16588491A JPH0510952A JP H0510952 A JPH0510952 A JP H0510952A JP 16588491 A JP16588491 A JP 16588491A JP 16588491 A JP16588491 A JP 16588491A JP H0510952 A JPH0510952 A JP H0510952A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- carrier
- enzyme
- immobilized
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000126 substance Substances 0.000 title description 24
- 239000000427 antigen Substances 0.000 claims abstract description 35
- 102000036639 antigens Human genes 0.000 claims abstract description 35
- 108091007433 antigens Proteins 0.000 claims abstract description 35
- 239000003507 refrigerant Substances 0.000 claims abstract description 5
- 238000001035 drying Methods 0.000 claims abstract description 4
- 238000007710 freezing Methods 0.000 claims abstract description 4
- 230000008014 freezing Effects 0.000 claims abstract description 3
- 238000004108 freeze drying Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 abstract description 15
- 108090000790 Enzymes Proteins 0.000 abstract description 15
- 239000012530 fluid Substances 0.000 abstract description 8
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- 238000000926 separation method Methods 0.000 abstract description 2
- 230000004913 activation Effects 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 description 22
- 239000011324 bead Substances 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 239000004793 Polystyrene Substances 0.000 description 11
- 229920002223 polystyrene Polymers 0.000 description 11
- 238000003018 immunoassay Methods 0.000 description 10
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 239000002953 phosphate buffered saline Substances 0.000 description 8
- 102000030902 Galactosyltransferase Human genes 0.000 description 7
- 108060003306 Galactosyltransferase Proteins 0.000 description 7
- 238000009739 binding Methods 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000010419 fine particle Substances 0.000 description 4
- 230000008105 immune reaction Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000013060 biological fluid Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 102000010911 Enzyme Precursors Human genes 0.000 description 2
- 108010062466 Enzyme Precursors Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 238000006757 chemical reactions by type Methods 0.000 description 2
- 239000005515 coenzyme Substances 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000002532 enzyme inhibitor Substances 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- GHCZTIFQWKKGSB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;phosphoric acid Chemical compound OP(O)(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O GHCZTIFQWKKGSB-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 108010006591 Apoenzymes Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 101000950981 Bacillus subtilis (strain 168) Catabolic NAD-specific glutamate dehydrogenase RocG Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101001011741 Bos taurus Insulin Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 102000016901 Glutamate dehydrogenase Human genes 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 238000003453 ammonium sulfate precipitation method Methods 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000002795 fluorescence method Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229910000464 lead oxide Inorganic materials 0.000 description 1
- 238000002796 luminescence method Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- YEXPOXQUZXUXJW-UHFFFAOYSA-N oxolead Chemical compound [Pb]=O YEXPOXQUZXUXJW-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- -1 prosthetic groups Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】本発明は、流体試料中の微量成
分、特に生物学的流体試料中の特定微量成分を測定する
に際して用いられる固定化担体の製造方法に関するもの
である。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a method for producing an immobilization carrier used for measuring a trace component in a fluid sample, particularly a specific trace component in a biological fluid sample.
【0002】[0002]
【発明の背景】生物学的流体試料中に極微量含有される
物質を検出する方法として、各種の分析法が開発されて
来ている。この分析法の一つとして、免疫反応をその原
理とするものがある。そして、この原理を用いた測定法
として種々のものが開発され、精度の高いものとして知
られている。BACKGROUND OF THE INVENTION Various analytical methods have been developed as a method for detecting a substance contained in a trace amount in a biological fluid sample. As one of the analysis methods, there is one that uses an immune reaction as its principle. Various measuring methods using this principle have been developed and are known to be highly accurate.
【0003】すなわち、1958年にBersonとY
allowが、放射性同位元素Iで標識した牛インシュ
リンと糖尿病患者血清中の抗インシュリン抗体を用い
て、血清中のインシュリンを測定することに成功して以
来、ラジオアイソトープを用いた免疫測定法が広く用い
られて来た。そして、これ以後、標識物質として放射性
同位元素以外のものも種々開発されて来た。例えば、酵
素、酵素基質、補酵素、酵素阻害物質、バクテリオファ
ージ、循環反応体、金属及び有機金属の錯体、有機補欠
分子族、化学発光性反応体及び螢光性分子等が挙げられ
る。That is, Berson and Y in 1958
Since allow succeeded in measuring serum insulin using bovine insulin labeled with radioisotope I and anti-insulin antibody in serum of diabetic patients, immunoassays using radioisotopes have been widely used. I've been taken. Since then, various substances other than radioisotopes have been developed as labeling substances. Examples include enzymes, enzyme substrates, coenzymes, enzyme inhibitors, bacteriophages, circulating reactants, metal and organometallic complexes, organic prosthetic groups, chemiluminescent reactants and fluorescent molecules.
【0004】ところで、免疫測定が行われるに際して
は、抗体(又は抗原)が固定化された担体が用いられ
る。この固定化担体は、抗体(又は抗原)溶液中に担体
を入れ、攪拌し、担体に抗体(又は抗原)を吸着させ、
その後凍結乾燥することにより製造されている。しかし
ながら、このようにして得られた固定化担体を用いての
免疫測定では、その測定値に変動が大きい場合があり、
再現性が低い問題点の有ることが判って来た。By the way, when immunoassay is performed, a carrier on which an antibody (or an antigen) is immobilized is used. This immobilization carrier is prepared by placing the carrier in an antibody (or antigen) solution and stirring it so that the antibody (or antigen) is adsorbed on the carrier.
It is then manufactured by freeze-drying. However, in the immunoassay using the thus obtained immobilization carrier, the measured value may vary greatly,
It turns out that there are problems with low reproducibility.
【0005】[0005]
【発明の開示】本発明の目的は、流体試料中の特定成分
を正確に、精度及び再現性良く定量できる技術を提供す
ることである。この本発明の目的は、抗体(又は抗原)
が固定化された担体を凍結乾燥することにより固定化担
体を製造する方法であって、不活性極低温冷媒で凍結し
た後、減圧乾燥することを特徴とする固定化担体の製造
方法によって達成される。DISCLOSURE OF THE INVENTION An object of the present invention is to provide a technique capable of accurately and precisely quantifying a specific component in a fluid sample. This object of the present invention is to provide an antibody (or antigen)
Is a method for producing an immobilized carrier by freeze-drying the immobilized carrier, which is achieved by a method for producing an immobilized carrier, which comprises freezing with an inert cryogenic refrigerant and then drying under reduced pressure. It
【0006】抗体(又は抗原)が物理的及び/又は化学
的に結合される担体は多孔質なものであることが好まし
く、このような担体の材料としてはケイ藻土、二酸化チ
タン、硫酸バリウム、酸化亜鉛、酸化鉛、微結晶セルロ
ース、ケイ砂、ガラス、シリカゲル、架橋デキストリ
ン、架橋ポリアクリルアミド、アガロース、架橋アガロ
ース、ポリスチレン等の各種の合成樹脂が挙げられる。
そして、このような素材の多孔質担体であれば、抗体
(又は抗原)が固定化される一次的な形状は粒子(ビー
ズ)状、棒状あるいはプレート状のものであっても差し
支えないが、粒子(ビーズ)状のものが好ましい。The carrier to which the antibody (or antigen) is physically and / or chemically bound is preferably porous, and the material for such carrier is diatomaceous earth, titanium dioxide, barium sulfate, or the like. Examples thereof include various synthetic resins such as zinc oxide, lead oxide, microcrystalline cellulose, silica sand, glass, silica gel, crosslinked dextrin, crosslinked polyacrylamide, agarose, crosslinked agarose and polystyrene.
If the porous carrier of such a material is used, the primary shape on which the antibody (or antigen) is immobilized may be particles (beads), rods or plates, but The shape of (beads) is preferable.
【0007】抗体又は抗原は、これら多孔質の不溶化担
体に、化学的及び/又は物理的に直接、あるいは間接的
に結合させることができる。結合方法として従来の手段
がそのまま採用されても良いが、例えば抗体または抗原
の溶液が入れられた容器内に、ポリスチレンビーズ等の
担体が粗く入れられたメッシュ状(バスケット状)の脚
付き容器を入れ、ポリスチレンビーズ等の担体を抗体ま
たは抗原溶液に浸し、又、容器の底部にマグネチック攪
拌子を置いておき、そしてこの状態においてマグネチッ
ク攪拌子を回転させ、ポリスチレンビーズ等の担体に回
転力を付与しない静止状態で抗体(又は抗原)溶液を流
動させることにより、ポリスチレンビーズ等の担体に均
一に抗体(又は抗原)を結合させる手段が好ましい。
尚、抗体(又は抗原)溶液の流動は攪拌子による攪拌手
段のみではなく、例えば噴流力を印加するようにしても
良く、どのような手段が用いられても良い。そして、ポ
リスチレンビーズ等の担体を静置状態にし、かつ、抗体
または抗原溶液に流動力を印加することにより抗体又は
抗原を担体に結合させた後、この固定化担体が凍結乾燥
されるのであるが、この固定化担体が入れられている前
記メッシュ状(バスケット状)の容器を取り出し、そし
て取り出したメッシュ状(バスケット状)の容器をその
まま液体窒素などの不活性極低温冷媒中に浸け、固定化
担体を瞬間凍結し、減圧下で乾燥することにより本発明
になる固定化担体が得られる。尚、不活性極低温冷媒と
しては、冷却温度が約−150℃以下程度のものである
ことが好ましく、このようなことから現実的には液体窒
素が最も使用される。The antibody or antigen can be bound chemically or / and physically directly or indirectly to these porous insolubilized carriers. Although conventional means may be directly adopted as the binding method, for example, a mesh-shaped (basket-shaped) container with legs in which a carrier such as polystyrene beads is roughly contained in a container containing a solution of an antibody or an antigen is used. Put, soak the carrier such as polystyrene beads in the antibody or antigen solution, and keep the magnetic stirrer at the bottom of the container.In this state, rotate the magnetic stirrer and rotate the carrier such as polystyrene beads with a rotating force. A means for uniformly binding the antibody (or antigen) to a carrier such as polystyrene beads by flowing an antibody (or antigen) solution in a stationary state in which no antibody is added is preferable.
The flow of the antibody (or antigen) solution is not limited to stirring means by a stirrer, for example, a jet force may be applied, and any means may be used. Then, the carrier such as polystyrene beads is allowed to stand, and after the antibody or antigen is bound to the carrier by applying a fluid force to the antibody or antigen solution, the immobilized carrier is freeze-dried. , Take out the mesh-shaped (basket-shaped) container in which the immobilization carrier is placed, and immerse the taken-out mesh-shaped (basket-shaped) container as it is in an inert cryogenic refrigerant such as liquid nitrogen to immobilize it. The immobilized carrier according to the present invention can be obtained by flash-freezing the carrier and drying it under reduced pressure. The inert cryogenic refrigerant preferably has a cooling temperature of about −150 ° C. or lower, and liquid nitrogen is most practically used because of this.
【0008】その他の点に関する結合技術については、
1976年、講談社発行、千畑一郎ほか2名編「実験と
応用 アフィニティクロマトグラフィー」(第1刷)、
1975年、講談社発行、山崎 誠ほか2名編「アフィ
ニティクロマトグラフィー」(第1版)を参考にでき
る。尚、結合反応後、標識抗体(又は抗原)の非特異反
応を排除する目的で、測定すべき特異的反応に関与しな
い蛋白質を担持させることができる。それらの代表的な
例としては、哺乳動物及び鳥類の正常血清蛋白質、アル
ブミン、スキムミルク、乳酸醗酵物、コラーゲン及びそ
れらの分解物質等が挙げられる。[0008] As for the combining technique regarding other points,
Published by Kodansha in 1976, Ichiro Chibata and 2 others, "Experimentation and Application Affinity Chromatography" (first edition),
In 1975, you can refer to "Affinity Chromatography" (1st edition) published by Kodansha and edited by Makoto Yamazaki and 2 others. After the binding reaction, a protein that does not participate in the specific reaction to be measured can be loaded for the purpose of eliminating the nonspecific reaction of the labeled antibody (or antigen). Typical examples thereof include normal mammalian and avian serum proteins, albumin, skim milk, lactic acid fermentation products, collagen, and degradation products thereof.
【0009】そして、上記のようにして得られた抗体
(又は抗原)が物理的及び/又は化学的に結合した不溶
化微粒子抗体(又は不溶化微粒子抗原)と酵素などで標
識された抗体(又は抗原)及び試料とを接触、免疫反応
させ、B/F分離した後、不溶化微粒子抗体(又は不溶
化微粒子抗原)に結合しないで遊離の状態で存在する酵
素標識体の酵素活性を例えば乾式分析素子で測定するこ
とで、試料中の抗原(又は抗体)が簡便な操作で、感
度、正確度、精度及び再現性良く、正確な測定が行われ
るのである。Then, the antibody (or antigen) obtained as described above is physically and / or chemically bound to the insolubilized fine particle antibody (or the insolubilized fine particle antigen) and the antibody (or antigen) labeled with an enzyme or the like. After contacting with the sample, immunoreacting, and performing B / F separation, the enzyme activity of the enzyme-labeled substance existing in a free state without binding to the insolubilized fine particle antibody (or insolubilized fine particle antigen) is measured by, for example, a dry analytical element Thus, the antigen (or antibody) in the sample can be accurately measured by a simple operation with good sensitivity, accuracy, precision and reproducibility.
【0010】免疫測定においては、試料としてあらゆる
形態の溶液、コロイド溶液などが使用しうるが、好まし
くは生物由来の流体試料、例えば血液、血漿、血清、脳
脊髄液、唾液、羊水、乳、尿、汗、肉汁等が挙げられ
る。測定しうる流体試料中での特定成分は、その特定成
分に特異的に結合する物質が存在しうる物質(物質群)
である。すなわち、ポリペプチド、蛋白質、複合蛋白
質、多糖類、脂質、複合脂質、核酸、ホルモン類、ビタ
ミン類、薬剤、抗生物質、農薬等が挙げられる。具体的
には、特開昭62−90539号公報や特開昭63−1
31062号公報に記載の物質(物質群)を挙げること
ができるが、これらに限定されるものではない。In the immunoassay, any form of solution, colloidal solution and the like can be used, but preferably a biological fluid sample such as blood, plasma, serum, cerebrospinal fluid, saliva, amniotic fluid, milk and urine. , Sweat, gravy, etc. A specific component in a measurable fluid sample is a substance (substance group) in which a substance that specifically binds to the specific component may exist.
Is. That is, examples thereof include polypeptides, proteins, complex proteins, polysaccharides, lipids, complex lipids, nucleic acids, hormones, vitamins, drugs, antibiotics, pesticides and the like. Specifically, JP-A-62-90539 and JP-A-63-1
The substances (substance groups) described in Japanese Patent No. 31062 can be mentioned, but the substances are not limited thereto.
【0011】免疫測定において用いられる標識物質とし
ては、例えば、酵素、酵素基質、酵素及び酵素前駆体の
活性を変化させる物質(酵素阻害物質、補欠分子族、補
酵素)、酵素前駆体、アポ酵素、螢光物質、放射性同位
元素などが挙げられる。具体的な物質としては、特開昭
62−90539号公報などに記載のものが挙げられる
が、好ましくは酵素、又は螢光物質であり、さらに好ま
しくはβ−D−ガラクトシダーゼ、アルカリホスファタ
ーゼ、ペルオキシダーゼ、グルコースオキシダーゼ、グ
ルタメートデヒドロゲナーゼ、アミラーゼなどの酵素で
ある。これらの酵素を標識物質とする場合、酵素反応
系、発色系は公知のものを使用できる。具体的には、特
開昭61−292060号公報、特開昭62−9053
9号公報、特開昭63−131062号公報、特開昭6
3−45562号公報、特願昭63−219893号明
細書に記載の物質(物質群)が挙げられるが、これらに
限定されるものではない。そして、これら標識物質の抗
体(抗原)への結合は、当業者間で知られている公知の
試薬と方法で行うことができ、例えば石川栄治、河合
忠、宮井潔 編「酵素免疫測定法(第2版)、医学書
院、1978年」や日本臨床病理学会編「臨床病理」臨
時増刊特集第53号「臨床検査の為のイムノアッセイ−
技術と応用−、臨床病理刊行会、1983年」などに記
載された方法を参考にすることができる。Examples of labeling substances used in immunoassay include enzymes, enzyme substrates, substances that change the activity of enzymes and enzyme precursors (enzyme inhibitors, prosthetic groups, coenzymes), enzyme precursors, apoenzymes. , Fluorescent substances, radioisotopes, etc. Specific substances include those described in JP-A-62-90539 and the like, preferably an enzyme or a fluorescent substance, more preferably β-D-galactosidase, alkaline phosphatase, peroxidase, Enzymes such as glucose oxidase, glutamate dehydrogenase and amylase. When these enzymes are used as the labeling substance, known ones can be used for the enzyme reaction system and the color development system. Specifically, JP-A-61-292060 and JP-A-62-9053.
9, JP-A-63-131062, JP-A-6-6
Examples thereof include substances (substance groups) described in JP-A-3-45562 and Japanese Patent Application No. 63-219893, but the present invention is not limited thereto. Then, the binding of these labeling substances to the antibody (antigen) can be performed by known reagents and methods known to those skilled in the art, for example, Eiji Ishikawa and Kawai.
Tadashi, Kiyoshi Miyai, "Enzyme-linked immunosorbent assay (2nd edition), Medical Shoin, 1978" and Japan Society for Clinical Pathology, "Clinical Pathology" Extra Edition Special Issue No. 53, "Immunoassays for Clinical Testing-
Techniques and applications-, Clinical Pathology Publication Society, 1983 ”, etc. can be referred to.
【0012】本発明で使用される抗体は、その由来を特
に限定されるものではなく、哺乳動物等に抗原を投与、
免疫して得られる抗血清、腹水液をそのままか、あるい
は従来公知の方法である硫酸ナトリウム沈澱法、硫酸ア
ンモニウム沈澱法、セファデックスゲルによるゲル濾過
法、イオン交換セルロースクロマトグラフィ法、電気泳
動法等(右田俊介偏「免疫化学」中山書店pp74〜8
8参照)で精製して用いることができる。あるいは、抗
原で感染した哺乳動物など(例えばマウス)の脾臓細胞
や骨髄腫細胞(ミエローマ)から雑種細胞(ハイブリド
ーマ)を得てモノクローナル抗体を作成し、これを特定
成分と特異的に結合しうる物質として使用すると特異性
が向上し、好ましい。又、これらの抗体はIgG、Ig
M、IgA、IgD、IgE各分画を用いることがで
き、或いはこれらの抗体を酵素処理してFab、Fa
b’又はF(ab’)2 といった活性抗体フラグメント
にして使用しても良い。さらに、これらの抗体は単一で
使用しても、複数の抗体を組み合わせて使用しても良
い。The origin of the antibody used in the present invention is not particularly limited, and the antigen is administered to mammals,
The antiserum and ascites fluid obtained by immunization may be used as they are, or may be a conventionally known method such as sodium sulfate precipitation method, ammonium sulfate precipitation method, gel filtration method using Sephadex gel, ion exchange cellulose chromatography method, electrophoresis method, etc. Shunsuke Bipolar "Immunochemistry" Nakayama Shoten pp74-8
8) and can be used after purification. Alternatively, a substance capable of specifically binding to a specific component by preparing a hybrid antibody (hybridoma) from spleen cells or myeloma cells (myeloma) of a mammal (eg, mouse) infected with an antigen, and producing a monoclonal antibody When used as, the specificity is improved, which is preferable. In addition, these antibodies are IgG, Ig
Fractions of M, IgA, IgD, and IgE can be used, or Fab and Fa can be obtained by treating these antibodies with an enzyme.
It may be used as an active antibody fragment such as b ′ or F (ab ′) 2 . Furthermore, these antibodies may be used alone or in combination of a plurality of antibodies.
【0013】本発明で使用する抗原は特異抗体と反応す
るものであり、ハプテン及びその誘導体を含有する。免
疫測定方法による反応型式としては、競合法、2抗体
法、サンドイッチ法などが挙げられるが、特に限定はさ
れない。又、他の生物活性物質(例えば、ビオチン、ア
ビジン)を利用した免疫測定方法も適用できる。本明細
書においては、流体試料中の特定成分を測定するのに反
応型式として免疫反応を挙げているが、免疫反応に準ず
る生物活性を示す物質の特異反応(本明細書では、この
特異反応も免疫反応に包含)を利用することも可能であ
る。The antigen used in the present invention reacts with a specific antibody and contains a hapten and its derivative. The reaction type by the immunoassay method includes, but is not particularly limited to, the competitive method, the antibody method, the sandwich method and the like. Further, an immunoassay method using another bioactive substance (for example, biotin, avidin) can also be applied. In the present specification, an immune reaction is mentioned as a reaction type for measuring a specific component in a fluid sample, but a specific reaction of a substance showing biological activity according to the immune reaction (this specific reaction is also referred to in the present specification). It is also possible to utilize (included in immune reaction).
【0014】標識に起因した信号は、吸光度法(比色
法) 、螢光法または発光法で検出することができ、測定
法としては信号の経時的変化を測定するレート測定法ま
たは一定時間後の信号を測定するエンドポイント測定法
で測定することができる。好ましくは吸光度法であり、
吸光度法(比色法) では紫外線、可視光、近赤外光を利
用することができる。The signal caused by the label can be detected by an absorbance method (colorimetric method), a fluorescence method or a luminescence method. As a measuring method, a rate measuring method for measuring a change with time of the signal or after a certain period of time is used. Can be measured by an endpoint measurement method that measures the signal of. The absorbance method is preferred,
The absorbance method (colorimetric method) can utilize ultraviolet light, visible light, and near infrared light.
【0015】[0015]
〔液体窒素を用いた凍結乾燥〕癌関連ヒトガラクトシル
トランスフェラーゼ(GAT)に対するマウスモノクロ
ーナル抗体を1Mの塩化ナトリウムを溶解した0.1M
炭酸塩緩衝液(pH9.5)に10μg/mlになるよ
う溶解し、この中にポリスチレンビーズ(積水化学#8
0)を浸漬し、4℃で一晩かけて固定化した。これをリ
ン酸緩衝生理的食塩水(PBS)で洗浄した後、1%B
SA−PBS溶液に37℃で24時間浸漬した。[Freeze-drying using liquid nitrogen] A mouse monoclonal antibody against cancer-associated human galactosyltransferase (GAT) was dissolved in 1M sodium chloride to give 0.1M.
It was dissolved in a carbonate buffer solution (pH 9.5) at 10 μg / ml, and polystyrene beads (Sekisui Chemical # 8) were added to the solution.
0) was immersed and fixed overnight at 4 ° C. After washing this with phosphate buffered saline (PBS), 1% B
It was immersed in the SA-PBS solution at 37 ° C. for 24 hours.
【0016】このようにして得られた抗体固定化ポリス
チレンビーズ1000個をバスケット状の容器(底辺1
0cm×10cm、高さ10cm)に入れ、液体窒素に
3分間容器ごと浸漬し、その後減圧下で冷却乾燥した。
尚、マウス抗GAT抗体は特願平2−54567号(発
明の名称「癌関連ヒト由来ガラクトース転移酵素に特異
的なモノクローナル抗体、それを産生するハイブリドー
マ及びそれを用いた検体中の癌関連ヒト由来ガラクトー
ス転移酵素の測定方法」平成2年3月6日出願)に記載
される方法で得た。すなわち、Cancer Rese
arch 48,5325(1988)に記載の方法に
従い、癌患者の腹水から精製したGATを抗原としてマ
ウスを免疫して得られた脾臓細胞を用い、常法に従って
細胞融合により抗GATモノクローナル抗体を産生する
ハイブリトーマを得、これより得たものである。1000 pieces of the antibody-immobilized polystyrene beads thus obtained were placed in a basket-like container (bottom 1
0 cm × 10 cm, height 10 cm), the container was immersed in liquid nitrogen for 3 minutes, and then cooled and dried under reduced pressure.
In addition, the mouse anti-GAT antibody is Japanese Patent Application No. 2-54567 (the title of the invention "a monoclonal antibody specific to a cancer-related human-derived galactosyltransferase, a hybridoma producing the same, and a cancer-related human-derived human in a specimen using the same. Method for measuring galactosyltransferase ”(filed on Mar. 6, 1990). That is, Cancer Rese
In accordance with the method described in Arch 48, 5325 (1988), anti-GAT monoclonal antibody is produced by cell fusion according to a conventional method using spleen cells obtained by immunizing mice with GAT purified from ascites of cancer patients as an antigen. A hybridoma was obtained and obtained from this.
【0017】〔比較冷1〕 〔−20℃のフリーザー冷却による凍結乾燥〕実施例1
と同様にして得た抗体固定化ポリスチレンビーズを1%
BSA−PBS溶液に37℃で24時間浸漬した。この
ポリスチレンビーズ1000個を1%BSA−PBSを
除去した後、−20℃のフリーザー中で30分間静置し
た後、減圧下で冷却乾燥した。[Comparative cooling 1] [Freeze-drying by freezer cooling at -20 ° C] Example 1
1% of antibody-immobilized polystyrene beads obtained in the same manner as
It was immersed in a BSA-PBS solution at 37 ° C. for 24 hours. After removing 1% BSA-PBS from 1000 polystyrene beads, the mixture was allowed to stand in a freezer at -20 ° C for 30 minutes, and then cooled and dried under reduced pressure.
【0018】〔免疫測定 GATの測定〕上記各例で得
たポリスチレンビーズを10U/ml、30U/ml、
90U/mlのGAT標準液0.05mlと1Mの塩化
ナトリウムを溶解した50mMリン酸緩衝液(pH6.
5)0.2mlとを混合した液の中に入れ、37℃で2
時間インキュベーションした。PBSで洗浄後、固定化
抗体とは異なる部位を認識するペルオキシダーゼ標識抗
GATモノクローナル抗体の1%BSA−PBS溶液
(0.5μg/ml)を0.25ml加え、室温で1時
間インキュベーションした。PBSで洗浄後0.02%
のH2 O2 と3mg/mlのo−フェニレンジアミンを
含むクエン酸−リン酸緩衝液(pH5.0)0.3ml
を加え、室温で30分間発色させた。その後、1Nの硫
酸1mlで発色反応を停止し、492nmの吸光度を測
定した。[Immunoassay GAT measurement] The polystyrene beads obtained in each of the above-mentioned examples were used in an amount of 10 U / ml, 30 U / ml,
0.05 ml of 90 U / ml GAT standard solution and 50 mM phosphate buffer solution (pH 6.
5) Place in a mixed solution of 0.2 ml and 2 at 37 ° C.
Incubated for hours. After washing with PBS, 0.25 ml of a 1% BSA-PBS solution (0.5 μg / ml) of a peroxidase-labeled anti-GAT monoclonal antibody that recognizes a site different from the immobilized antibody was added, and the mixture was incubated at room temperature for 1 hour. 0.02% after washing with PBS
Citrate-phosphate buffer (pH 5.0) 0.3 ml containing H 2 O 2 and 3 mg / ml o-phenylenediamine
Was added and color was developed for 30 minutes at room temperature. Then, the color reaction was stopped with 1 ml of 1N sulfuric acid, and the absorbance at 492 nm was measured.
【0019】各々のものについてn=25で測定し、変
動係数CVを求めたので、その結果を下記の表に示す。 表 10U/ml 30U/ml 90U/ml 実施例1 5.2% 4.8% 4.2% 比較例1 8.7% 6.6% 5.7% これによれば、本発明により得られる抗体(又は抗原)
が固定化された担体を用いての免疫測定法は、変動係数
が格段に小さく、流体試料中の特定成分を正確に、精度
及び再現性良く定量できることが判る。The coefficient of variation CV was obtained by measuring each of the samples at n = 25, and the results are shown in the table below. Table 10 U / ml 30 U / ml 90 U / ml Example 1 5.2% 4.8% 4.2% Comparative Example 1 8.7% 6.6% 5.7% According to the present invention Antibody (or antigen)
It can be seen that the immunoassay method using a carrier on which is immobilized has a remarkably small coefficient of variation, and a specific component in a fluid sample can be accurately, accurately and reproducibly quantified.
Claims (1)
凍結乾燥することにより固定化担体を製造する方法であ
って、不活性極低温冷媒で凍結した後、減圧乾燥するこ
とを特徴とする固定化担体の製造方法。Claim: What is claimed is: 1. A method for producing an immobilized carrier by freeze-drying a carrier on which an antibody (or an antigen) is immobilized, which comprises decompressing after freezing with an inert cryogenic refrigerant. A method for producing an immobilized carrier, which comprises drying.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP16588491A JPH0510952A (en) | 1991-07-05 | 1991-07-05 | Preparation of carrier containing immobilized substance |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP16588491A JPH0510952A (en) | 1991-07-05 | 1991-07-05 | Preparation of carrier containing immobilized substance |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH0510952A true JPH0510952A (en) | 1993-01-19 |
Family
ID=15820811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP16588491A Pending JPH0510952A (en) | 1991-07-05 | 1991-07-05 | Preparation of carrier containing immobilized substance |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0510952A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5878807A (en) * | 1996-02-16 | 1999-03-09 | Takahashi; Kei | Fluid channeling unit |
US5954129A (en) * | 1996-02-14 | 1999-09-21 | Takahashi; Kei | Flow control unit |
WO2011114779A1 (en) | 2010-03-17 | 2011-09-22 | 日本ゼオン株式会社 | Medical inflation/deflation drive device |
-
1991
- 1991-07-05 JP JP16588491A patent/JPH0510952A/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5954129A (en) * | 1996-02-14 | 1999-09-21 | Takahashi; Kei | Flow control unit |
US5878807A (en) * | 1996-02-16 | 1999-03-09 | Takahashi; Kei | Fluid channeling unit |
WO2011114779A1 (en) | 2010-03-17 | 2011-09-22 | 日本ゼオン株式会社 | Medical inflation/deflation drive device |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US3791932A (en) | Process for the demonstration and determination of reaction components having specific binding affinity for each other | |
JP3257795B2 (en) | Unit-of-use reagent composition for specific binding assays | |
USRE31006E (en) | Process for the demonstration and determination of reaction components having specific binding affinity for each other | |
USRE29169E (en) | Process for the demonstration and determination of reaction components having specific binding affinity for each other | |
EP0609265B1 (en) | Unit-of-use reagent composition for specific binding assays | |
US5437981A (en) | Method for the immunological determination of ligands | |
US5043288A (en) | Immobilize molecular binding partners to contact activating supports | |
JPH01209370A (en) | Method and apparatus for measuring immunologically active substance | |
JPH0510952A (en) | Preparation of carrier containing immobilized substance | |
EP0607209B1 (en) | Unit-of-use reagent compositions for specific binding assays | |
JPS61186855A (en) | Method of measuring combining capacity of globulin forming thyroxine | |
JP2816767B2 (en) | Method for producing immobilized antibody | |
JPH0587811A (en) | Manufacture of carrier for fixing | |
JPH04337461A (en) | Manufacture of fixed carrier | |
JPH04216467A (en) | Immunoassay | |
JPH06313766A (en) | Carrier with immobilized antibody, manufacture thereof and immunologically measuring method by the same carrier | |
JPH04221762A (en) | Immunological measuring method | |
JPH07113805A (en) | Producing method of reference standard for immunoreaction measurement and immunologic measuring method using the same | |
JPH06148187A (en) | Immunological measuring method | |
JPH04357458A (en) | Immunoassay method | |
CA2034922A1 (en) | Method for the immunological determination of ligands | |
JPH04363662A (en) | Manufacture of immobilizing carrier | |
JPH04242165A (en) | Immunological measuring method | |
JPH04249769A (en) | Immunoassay | |
JPH05297004A (en) | Manufacture of immobilization carrier |